Curida

Executive Summary

Curida is a European Contract Development and Manufacturing Organization (CDMO) specializing in the sterile fill-finish of biologics and liquid medicines. Headquartered in Oslo, Norway, and founded in 1987, the company leverages proprietary Blow-Fill-Seal and nasal spray technologies to provide preservative-free solutions for nasal, ophthalmic, and injectable drug delivery. Curida supports pharmaceutical partners from clinical development through commercial manufacturing, ensuring the safe supply of life-improving products. With the global biologics market expanding and outsourcing trends accelerating, Curida is positioned to capture growth through its differentiated technology platforms and focus on high-quality sterile production. Despite its established track record, Curida operates as a private company with limited public financial disclosures, which constrains visibility into its operational performance and pipeline. The company's near-term growth hinges on securing new client contracts, expanding manufacturing capacity, and achieving regulatory milestones. The CDMO market is highly competitive, with larger players dominating the landscape, but Curida's niche in specialized delivery systems offers a competitive edge. Overall, the company demonstrates solid potential within its segment, but conviction is tempered by a lack of transparency and the need for tangible near-term catalysts.

Upcoming Catalysts (preview)

• Q3 2026New commercial manufacturing contract for a biologic product60% success
• Q4 2026Completion of capacity expansion at Oslo facility70% success
• Q2 2026FDA approval of a client's drug product manufactured by Curida50% success